Effect of Yiqi Yangyin Prescription on Lipid Metabolism in Rats with Type 2 Diabetes / 中国实验方剂学杂志

Objective:To observe the effect of Yiqi Yangyin prescription on lipid metabolism in type 2 diabetes rat model induced by high fat diet combined with intraperitoneal injection of streptozocin （STZ）， and explore its mechanism in regulation of lipid metabolism. Method:The rats were fed with high-fat diet for 4 weeks， and intraperitoneal injection of STZ was provided to establish diabetes model. The diabetic rats were randomly divided into model group， Yiqi Yangyin prescription high dose group， medium dose group and low dose group （9.00， 4.50， 2.25 g·kg^-1） and metformin group （0.20 g·kg^-1）. Another blank control group was set up. The high， medium and low dose groups were given with different oral doses of Yiqi Yangyin prescription granules， metformin was given in metformin group， the model group and the blank group received the same volume of normal saline. Intragastric administration was given for three weeks， and then the weight and blood glucose were measured. Automatic biochemical analyzer was used to detect triglyceride （TG）， total cholesterol （TC）， low density lipoprotein cholesterol （LDL-C）， high density lipoprotein cholesterol （HDL-C）， aspartate aminotransferase （AST）， alanine aminotransferase （ALT）， alkaline phosphatase （ALP）， and content of total protein （TP）. Hematoxylin-eosin （HE） staining was used to observe the pathological changes of liver tissues in each group. Periodic acid-schiff stain （PAS） staining was used to observe the pathological changes of liver glycogen. The lipid changes of liver tissues were observed by oil red O staining. The expression of adenosine monophosphate activated protein kinase （AMPK）/ sterol regulatory element binding protein 1c （SREBP1c）/acetyl-coenzyme A carboxylase （ACC1）/peroxisome proliferator activated re-ceptor <italic>α</italic> （PPAR<italic>α</italic>） pathway in liver tissues was observed by Western blot. Result:Compared with the blank group， TG， CHO， LDL-C， AST， ALT and ALP significantly increased and HDL-C significantly decreased in the model group （<italic>P</italic><0.05， <italic>P</italic><0.01）. Compared with the model group， TG and LDL-C contents significantly decreased （<italic>P</italic><0.05， <italic>P</italic><0.01）and LDL-C contents significantly increased in Yiqi Yangyin prescription groups （<italic>P</italic><0.05）. Histomorphology showed that Yiqi Yangyin prescription significantly reduced the degree of hepatocyte intercellular vacuoles and steatosis in liver， and significantly reduced the lipid area of liver tissue. Compared with the blank group， the protein expression levels of p-AMPK<italic>α</italic>， PPAR<italic>α</italic>， SREBP-1 （plasma） in the liver tissues significantly decreased in the model group， but such expression levels increased after treatment with Yiqi Yangyin prescription （<italic>P</italic><0.05， <italic>P</italic><0.01）， compared with the blank group， the protein expression levels of p-ACC1 and SREBP-1 （nuclear） significantly increased （<italic>P</italic><0.01） in model group， but such expression significantly decreased after treatment with Yiqi Yangyin prescription （<italic>P</italic><0.05， <italic>P</italic><0.01）. Conclusion:Yiqi Yangyin prescription can significantly reduce blood lipid in the diabetic rats caused by high-fat feed combined with STZ. The decrease of blood lipid in the type 2 diabetes rats may be related to the influence on AMPK/ACC1/SREBP-1/PPAR pathway in rat liver.

Effect of Yiqi Yangyin prescription in treatment of dilated cardiomyopathy: a Meta-analysis of randomized controlled trials.

OBJECTIVE: To evaluate the therapeutic effect of Yiqi Yangyin prescription for dilated cardiomyopathy (DCM). METHODS: Electronic databases were searched for relevant clinical randomized controlled trials of DCM treatment using Yiqi Yangyin prescription (Shengmai and Zhigancao decoction). Databases searched included PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine from January 1, 1985, to October 31, 2015. After literature screening and data extraction according to previously determined exclusion criteria, data were analyzed using RevMan 5.3 and Stata 12.0. Study heterogeneity was evaluated using the I 2 test and Cochran's Q test. Egger's test was used to detect publication bias. RESULTS: Nineteen trials involving 1024 participants were included in the Meta-analysis. Of these, 15 used Shengmai (treatment group: 421 cases; control group: 344 cases) and 4 used Zhigancao decoction (treatment group: 133 cases; control group: 126 cases). A Meta-analysis demonstrated that the total curative effect was significantly improved by combining Shengmai with conventional treatment [relative risk (RR) = 1.32, 95% confidence intervals (CI) (1.22, 1.43), P < 0.01]. Left ventricular ejection fraction [standard mean difference (SMD) = 1.13, 95% CI (0.55, 1.70), P < 0.01] and left ventricular end diastolic [SMD = -0.46, 95% CI (-0.70, -0.23), P < 0.01] were also improved. Adding Zhigancao decoction achieved the same effect [total efficiency of RR = 1.34, 95% CI (1.16, 1.54), P < 0.01]. CONCLUSION: Compared with conventional therapy, Yiqi Yangyin prescription can significantly improve the curative effect, increase left ventricular ejection fraction, and reduce left ventricular end diastolic. Thus, it can effectively improve heart function in patients with DCM.